- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05974527
Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency Department
July 26, 2023 updated by: Dana Im, MD, MPHIL, MPP, Brigham and Women's Hospital
This is a single-arm pilot study to examine the impact of BXCL501 (sublingual film formulation of dexmedetomidine) administration on reducing the severity of undifferentiated acute agitation in patients presenting to the emergency department with underlying bipolar disorder or schizophrenia.
This study is designed to evaluate BXCL501 for its FDA-approved indication -- treatment of agitation associated with bipolar disorder or schizophrenia -- applied in the emergency department setting.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
This pilot study will enroll 30 male and female adults with primary psychiatric complaint and a documented diagnosis of bipolar I disorder, bipolar II disorder, schizophrenia, schizoaffective disorder, or schizophreniform disorder, presenting to the emergency department with clinical signs of acute agitation.
Eligible subjects will receive an initial dose of BXCL501 (180mcg) and a repeat dose (90mcg) 2 hours after the first BXCL501 dose in the event of persistent or recurrent agitation (up to two repeat doses) while under medical supervision in the emergency department.
Efficacy and safety assessments will be conducted periodically before and after dosing.
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Dana Im, MD
- Phone Number: 617-732-5640
- Email: dim@bwh.harvard.edu
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- English speaking adults age ≥18 years
- Patients with an established diagnosis of (1) bipolar I disorder, (2) bipolar II disorder, (3) schizophrenia, (4) schizoaffective disorder, or (5) schizophreniform disorder
- Judged to be clinically agitated at the time of Screening and Baseline with a AMSS ≥2
- Able to read, understand, and provide written informed consent
- Subject judged to be likely capable of self-administration of BXCL501 sublingually or buccally
Exclusion Criteria:
- Likely to be discharged, admitted, or transferred from the ED within 6 hours after study medication administration
- Administration of benzodiazepines or antipsychotic drugs in the 2 hours before study treatment
- Treatment with alpha-1 noradrenergic antagonists
- Female patients who are pregnant or are breastfeeding
- Hypotension (systolic blood pressure <100 mmHg or diastolic blood pressure <60 mmHg) and/or bradycardia (heart rate <55 beats per minute) at the time of Screening or Baseline evaluation
- History of dysautonomia
- Patient with a known diagnosis of familial long QT syndrome, second degree or third degree atrioventricular block without pacemaker, or sick sinus syndrome
- Patients with serious or unstable medical illnesses determined by the study investigators or qualified designees
- Patients with history of allergic reactions to dexmedetomidine
- Patients previously enrolled and completed the current study
- Patients actively enrolled in other ED-based studies involving pharmacological or behavioral interventions
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention - BXCL501
|
Enrolled participants will receive an initial dose of BXCL501 180mcg.
Following the FDA dosing suggestions, participants with mild or moderate hepatic impairment (Child-Pugh Class A or B) will receive a reduced initial dose of 120mcg and participants with severe hepatic impairment (Child-Pugh Class C) will receive a reduced initial dose of 90mcg.
Geriatric patients (≥ 65 years old) will receive a reduced initial dose of 120mcg.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Absolute change from baseline in the Altered Mental Status Scale (AMSS) score
Time Frame: 120 minutes
|
AMSS is a 9-point scale ranging from -4 (most sedated) to 4 (most agitated).
|
120 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Absolute change from baseline in the Richmond Agitation Sedation Scale (RASS) score
Time Frame: 120 minutes
|
RASS is a 10-point scale with four levels of anxiety or agitation (+1 to +4), one denoting a calm, alert state (0), and five levels of sedation (-1 to -5).
|
120 minutes
|
Absolute change from baseline in the Behavioral Activity Rating Scale (BARS) score
Time Frame: 120 minutes
|
BARS is a 7-point scale ranging from 1 (difficult or unable to arouse) to 7 (violent, requires restraints).
|
120 minutes
|
Absolute change from baseline in the Broset Violence Checklist (BVC) score
Time Frame: 120 minutes
|
BVC is a six-item instrument with a total score ranging from 0 (no agitation) to 6 (severely agitated).
|
120 minutes
|
Times, in minutes, from BXCL501 administration to adequate sedation, defined as Altered Mental Status Scale (AMSS) score <1
Time Frame: To be determined - will be measured for 120 minutes
|
AMSS is a 9-point scale ranging from -4 (most sedated) to 4 (most agitated).
|
To be determined - will be measured for 120 minutes
|
Times, in minutes, from BXCL501 administration to adequate sedation, defined as Richmond Agitation Sedation Scale (RASS) score <1
Time Frame: To be determined - will be measured for 120 minutes
|
RASS is a 10-point scale with four levels of anxiety or agitation (+1 to +4), one denoting a calm, alert state (0), and five levels of sedation (-1 to -5).
|
To be determined - will be measured for 120 minutes
|
Times, in minutes, from BXCL501 administration to adequate sedation, defined as Behavioral Activity Rating Scale (BARS) score <5
Time Frame: To be determined - will be measured for 120 minutes
|
BARS is a 7-point scale ranging from 1 (difficult or unable to arouse) to 7 (violent, requires restraints).
|
To be determined - will be measured for 120 minutes
|
Times, in minutes, from BXCL501 administration to adequate sedation, defined as Broset Violence Checklist (BVC) score <1
Time Frame: To be determined - will be measured for 120 minutes
|
BVC is a six-item instrument with a total score ranging from 0 (no agitation) to 6 (severely agitated).
|
To be determined - will be measured for 120 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
September 1, 2023
Primary Completion (Estimated)
September 30, 2025
Study Completion (Estimated)
June 30, 2026
Study Registration Dates
First Submitted
July 26, 2023
First Submitted That Met QC Criteria
July 26, 2023
First Posted (Actual)
August 3, 2023
Study Record Updates
Last Update Posted (Actual)
August 3, 2023
Last Update Submitted That Met QC Criteria
July 26, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Nervous System Diseases
- Mood Disorders
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Disease Attributes
- Schizophrenia Spectrum and Other Psychotic Disorders
- Dyskinesias
- Psychomotor Disorders
- Bipolar and Related Disorders
- Emergencies
- Schizophrenia
- Psychotic Disorders
- Psychomotor Agitation
- Bipolar Disorder
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Hypnotics and Sedatives
- Dexmedetomidine
Other Study ID Numbers
- 2023p001864
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Rakitzi, StavroulaActive, not recruiting
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
NYU Langone HealthNot yet recruitingTreatment-resistant SchizophreniaUnited States
Clinical Trials on Sublingual film containing dexmedetomidine (BXCL501)
-
BioXcel Therapeutics IncCognitive Research CorporationCompletedDementia | Agitation,PsychomotorUnited States
-
BioXcel Therapeutics IncCognitive Research CorporationCompletedBipolar Disorder | Agitation,Psychomotor | Agitation Associated With Bipolar DisorderUnited States
-
BioXcel Therapeutics IncCognitive Research CorporationCompletedSchizophrenia | AgitationUnited States
-
BioXcel Therapeutics IncCognitive Research CorporationCompletedSchizophrenia | Schizoaffective Disorder | Agitation | Schizo Affective Disorder | Schizophreniform DisordersUnited States
-
Pharmacotherapies for Alcohol and Substance Use...Yale University; United States Department of Defense; VA Connecticut Healthcare... and other collaboratorsNot yet recruitingEffect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient StudyPost Traumatic Stress Disorder (PTSD) | Alcohol Use Disorder (AUD)United States
-
BioXcel Therapeutics IncLotus Clinical Research, LLCRecruitingSchizophrenia | Bipolar Disorder | Schizo Affective Disorder | Agitation,Psychomotor | Schizophreniform DisordersUnited States
-
Pharmacotherapies for Alcohol and Substance Use...Yale University; United States Department of Defense; VA Connecticut Healthcare... and other collaboratorsCompletedPost Traumatic Stress Disorder (PTSD) | Alcohol Use Disorder (AUD)United States
-
Johns Hopkins UniversityNational Institutes of Health (NIH)CompletedPharmacokinetics | Peanut Allergy | ImmunotherapyUnited States
-
BioXcel Therapeutics IncCognitive Research CorporationRecruitingSchizophrenia | Bipolar Disorder I | Schizo-Affective Disorder | Schizophreniform; Schizophrenic | Bipolar Disorder IIUnited States
-
Khon Kaen UniversityNot yet recruitingOral MucosaThailand